Draganov DI, Teiber JF, Watson C, Bisgaier C, Nemzek J, Remick D, Standiford T, La Du BN (2010)
PON1 and oxidative stress in human sepsis and an animal model of sepsis
Advances in Experimental Medicine & Biology 660: 89
Teiber JF, Billecke SS, La Du BN, Draganov DI (2007)
Estrogen esters as substrates for human paraoxonases
Archives of Biochemistry & Biophysics 461: 24
Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN (2005)
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities
J Lipid Res 46: 1239
Teiber JF, Draganov DI, La Du BN (2004)
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH
J Lipid Res 45: 2260
Rosenblat M, Draganov DI, Watson CE, Bisgaier CL, La Du BN, Aviram M (2003)
Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress
Arterioscler Thromb Vasc Biol 23: 468
Teiber JF, Draganov DI, La Du BN (2003)
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3
Biochemical Pharmacology 66: 887
Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN (2002)
Current progress on esterases: from molecular structure to function
Drug Metabolism & Disposition: The Biological Fate of Chemicals 30: 488
Brushia RJ, Forte TM, Oda MN, La Du BN, Bielicki JK (2001)
Baculovirus-mediated expression and purification of human serum paraoxonase 1A
J Lipid Res 42: 951
La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA (2001)
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals
Drug Metabolism & Disposition: The Biological Fate of Chemicals 29: 566
Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du BN (1999)
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
Free Radic Biol Med 26: 892
Billecke SS, Primo-Parmo SL, Dunlop CS, Doorn JA, La Du BN, Broomfield CA (1999)
Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate
Chemico-Biological Interactions 119-120: 251
Doorn JA, Sorenson RC, Billecke SS, Hsu C, La Du BN (1999)
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase
Chemico-Biological Interactions 119-120: 235
Haley RW, Billecke S, La Du BN (1999)
Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans
Toxicol Appl Pharmacol 157: 227
La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ (1999)
On the physiological role(s) of the paraoxonases
Chemico-Biological Interactions 119-120: 379
La Du BN, Furlong CE, Reiner E (1999)
Recommended nomenclature system for the paraoxonases
Chemico-Biological Interactions 119-120: 599
Naguib M, Gomaa M, Samarkandi AH, Bevan DR, Akkielah AK, Watson C, Billecke S, La Du BN (1999)
Increased plasma cholinesterase activity and mivacurium resistance: report of a family
Anesthesia & Analgesia 89: 1579
Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN (1999)
Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity
Arterioscler Thromb Vasc Biol 19: 2214
Sorenson RC, Aviram M, Bisgaier CL, Billecke S, Hsu C, La Du BN (1999)
Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase
Chemico-Biological Interactions 119-120: 243
Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN (1998)
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R
Arterioscler Thromb Vasc Biol 18: 1617
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998)
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
J Clinical Investigation 101: 1581
Primo-Parmo SL, Lightstone H, La Du BN (1997)
Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase
Pharmacogenetics 7: 27
Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AF, Innis JW, La Du BN (1996)
Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene
American Journal of Human Genetics 58: 52
Primo-Parmo SL, Sorenson RC, Teiber JF, La Du BN (1996)
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
Genomics 33: 498
Greenberg CP, Primo-Parmo SL, Pantuck EJ, La Du BN (1995)
Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods
Anesthesia & Analgesia 81: 419
La Du BN (1995)
Butyrylcholinesterase variants and the new methods of molecular biology [editorial; comment]
Acta Anaesthesiologica Scandinavica 39: 139
Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN (1995)
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
Proc Natl Acad Sci U S A 92: 7187
La Du BN, Adkins S, Kuo CL, Lipsig D (1993)
Studies on human serum paraoxonase/arylesterase
Chemico-Biological Interactions 87: 25
Nogueira CP, Evans DA, La Du BN (1993)
The paraoxonase polymorphism in a Saudi Arabian population
Pharmacogenetics 3: 144
Bartels CF, James K, La Du BN (1992)
DNA mutations associated with the human butyrylcholinesterase J-variant
American Journal of Human Genetics 50: 1104
Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN (1992)
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites
American Journal of Human Genetics 50: 1086
Hajra A, Sorenson RC, La Du BN (1992)
Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes
Pharmacogenetics 2: 78
Hidaka K, Iuchi I, Yamasaki T, Ohhara M, Shoda T, Primo-Parmo SL, La Du BN (1992)
[Identification of two different genetic mutation associated with silent phenotypes for human serum cholinesterase in Japanese]
Rinsho Byori 40: 535
Jensen FS, Bartels CF, La Du BN (1992)
Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families
Pharmacogenetics 2: 234
Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, van der Spek AF, Lockridge O, La Du BN (1992)
Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase
American Journal of Human Genetics 51: 821
Adkins S, Vaughan TA, Bartels CF, La Du BN, Lockridge O (1991)
Poster: Expression of the fluoride variant of human butyrylcholinesterase in chinese hamster ovary cells
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 196
Allderdice PW, Gardner HA, Galutira D, Lockridge O, La Du BN, McAlpine PJ (1991)
The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26
Genomics 11: 452
Arpagaus M, Chatonnet A, Masson P, Newton M, Vaughan TA, Bartels CF, Nogueira CP, La Du BN, Lockridge O (1991)
Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates
Journal of Biological Chemistry 266: 6966
Arpagaus M, Vaughan TA, La Du BN, Lockridge O, Masson P, Chatonnet A, Newton M, Taylor P (1991)
Poster: Use of the polymerase chain reaction for homology probing of butyrylchoIinesterase (BCHE) in several animal species
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 194
Bartels CF, Lockridge O, La Du BN, van der Spek AF, Rubinstein HM, Lubrano T (1991)
Poster: DNA Coding for the K polymorphism in linkage disequilibrium with atypical human butyrylcholinesterase complicates phenotyping
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 191
Bartels CF, Nogueira CP, McGuire MC, Adkins S, Lockridge O, La Du BN, Rubinstein HM, Lubrano T, van der Spek AF, Lightstone H (1991)
Poster: Identification of two different mutations associated with human butyrylcholinesterase fluoride resistance in serum
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 190
Gan KN, Smolen A, Eckerson HW, La Du BN (1991)
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities
Drug Metabolism & Disposition: The Biological Fate of Chemicals 19: 100
Hajra A, La Du BN (1991)
Poster: Diagnosis of human butyrylcholinesterase variants using biotinylated oligonucleotide probes
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 201
Jensen FS, Bartels CF, La Du BN (1991)
Poster: A DNA point mutation associated with the H-variant of human butyrylcholinesterase
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 189
La Du BN, Bartels CF, Lockridge O (1991)
Poster: Practical consequences of having more than one mutation within the same butyrylcholinesterase gene
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 192
La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O (1991)
Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing
Cellular Molecular Neurobiology 11: 79
Lockridge O, Bartels CF, Nogueira CP, Arpagaus M, Adkins S, La Du BN (1991)
Poster: Nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 193
McAlpine PJ, Dixon M, Allderdice PW, Lockridge O, La Du BN (1991)
The butyrylcholinesterase gene (BCHE) at 3q26.2 shows two RFLPs
Nucleic Acids Research 19: 5088
Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN (1991)
Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase
Drug Metabolism & Disposition: The Biological Fate of Chemicals 19: 107
Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O (1990)
Structure of the gene for human butyrylcholinesterase. Evidence for a single copy
Biochemistry 29: 124
Bartels CF, van der Spek AF, La Du BN (1990)
Two polymorphisms in the non-coding regions of the BCHE gene
Nucleic Acids Research 18: 6171
La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, van der Spek AF, Lockridge O (1990)
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants
Clinical Biochemistry 23: 423
Nogueira CP, McGuire MC, Graeser C, Bartels CF, Arpagaus M, van der Spek AF, Lightstone H, Lockridge O, La Du BN (1990)
Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG)
American Journal of Human Genetics 46: 934
La Du BN (1989)
Identification of human serum cholinesterase variants using the polymerase chain reaction amplification technique [published erratum appears in Trends Pharmacol Sci 1989 Sep;10(9):345]
Trends in Pharmacological Sciences 10: 309
McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, van der Spek AF, Lockridge O, La Du BN (1989)
Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase
Proc Natl Acad Sci U S A 86: 953
Nogueira CP, McGuire MC, Bartels CF, van der Spek AF, Lightstone H, Lockridge O, La Du BN (1989)
Identification of a frameshift mutation (gly 117, GGT-to-GGAG) responsible for a silent phenotype of human serum cholinesterase. (Abstract)
American Journal of Human Genetics 45 (suppl.): A210
Lockridge O, Adkins S, La Du BN (1987)
Location of disulfide bonds within the sequence of human serum cholinesterase
Journal of Biological Chemistry 262: 12945
McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O (1987)
Brain cDNA clone for human cholinesterase
Proceedings of the National Academy of Sciences of the United States of America 84: 6682
La Du BN, Lockridge O (1986)
Molecular biology of human serum cholinesterase.
Federation Proceedings 45: 2965
Lockridge O, La Du BN (1986)
Amino acid sequence of the active site of human serum cholinesterase from usual, atypical, and atypical-silent genotypes
Biochemical Genetics 24: 485
Eckerson HW, La Du BN (1984)
A mathematical model for evaluating the reaction of paraoxon with human serum cholinesterase and with polymorphic forms of paraoxonase
Drug Metabolism & Disposition: The Biological Fate of Chemicals 12: 57
La Du BN, Eckerson HW (1984)
The polymorphic paraoxonase/arylesterase isozymes of human serum
Federation Proceedings 43: 2338
Eckerson HW, Oseroff A, Lockridge O, La Du BN (1983)
Immunological comparison of the usual and atypical human serum cholinesterase phenotypes
Biochemical Genetics 21: 93
Lockridge O, La Du BN (1982)
Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase
Journal of Biological Chemistry 257: 12012
Myers C, Lockridge O, La Du BN (1982)
Hydrolysis of methylprednisolone acetate by human serum cholinesterase
Drug Metabolism & Disposition: The Biological Fate of Chemicals 10: 279
Valentino RJ, Lockridge O, Eckerson HW, La Du BN (1981)
Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies
Biochemical Pharmacology 30: 1643
Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN (1980)
Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase
Journal of Pharmacology & Experimental Therapeutics 215: 1
Lockridge O, Eckerson HW, La Du BN (1979)
Interchain disulfide bonds and subunit organization in human serum cholinesterase
Journal of Biological Chemistry 254: 8324
Lockridge O, La Du BN (1978)
Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number
Journal of Biological Chemistry 253: 361
La Du BN (1972)
Isoniazid and psuedocholinesterase polymorphisms
Federation Proceedings 31: 1276
La Du BN (1972)
Genetic determimants in drug action
Adv Biol Skin 12: 95
La Du BN (1972)
Pharmacogenetics: defective enzymes in relation to reactions to drugs
Annu Rev of Med 23: 453
La Du BN, Dewald B (1970)
Genetic regulation of plasma cholinesterase in man.
Advances in Enzyme Regulation 9: 317
Clark SW, Glaubiger GA, La Du BN (1968)
Properties of plasma cholinesterase variants
Annals of the New York Academy of Sciences 151: 710
Swift MR, La Du BN (1966)
A rapid screening test for atypical serum-cholinesterase
Lancet 1: 513